Full-Time

Senior Medical Science Liaison-Epilepsy

Posted on 11/23/2025

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$176k - $264k/yr

+ Bonus + Equity Grants

Texas, USA + 3 more

More locations: Mississippi, USA | Oklahoma, USA | Louisiana, USA

Hybrid

Must live within 60 miles of a major airport.

Category
Biology & Biotech (2)
,
Requirements
  • Ability to research and critically analyze and communicate complex scientific and medical information and data.
  • Ability and willingness to travel at least 60% of work days, Driving required.
  • Clear and concise communication and presentation skills.
  • Excellent planning and organization skills, with high-level attention to detail and accuracy.
  • Strong strategic mindset.
  • Highly self-motivated and ability to work autonomously.
  • Ability to learn quickly, be flexible and results-focused in a rapidly changing environment.
  • Excellent negotiation skills.
  • Demonstrated skills in inter-personal relationship building, networking, collaboration and teamwork.
  • Strong capabilities working with digital platforms and tools are required
  • Excellent command of spoken English.
  • MS/Advanced Practice Degree in scientific and/or medical discipline with a minimum of 5 years experience in Epilepsy -or- MD, PharmD, or PhD is required
  • MSL experience in Neurology is required and experience in Epilepsy is strongly preferred
  • Minimum 3 years experience as a Medical Science Liaison with a strong track record of success
  • This is a field position and applicants must be willing to travel 60-80% time
  • Valid driver’s license and live within 60 miles of a major airport
Responsibilities
  • Identify and develop peer-to-peer relationships with key opinion leaders (KOLs) and healthcare providers within the Epilepsy therapeutic area
  • Develop and execute territory plans in alignment with US Medical Affairs plans
  • Identify and communicate key clinical and research issues and insights from KOLs to appropriate departments
  • Participate in medical education for healthcare professionals (HCPs) through on-site presentations at healthcare institutions, investigator meetings, national conferences, advisory boards, or regional meetings
  • Provide scientific support for additional activities such as medical congress staffing, advisory boards, and sales training initiatives
  • Maintains an up to date and high-level knowledge of the therapy area, Jazz products, new and emerging areas of research, therapeutic issues and trends, and competitive landscape.
  • Establishes reputation as a trustworthy and knowledgeable source of scientific and medical information for the healthcare community.
  • Supports development of Jazz Pharmaceuticals positioning as the scientific authority in Epilepsy. Attends appropriate scientific congresses to stay abreast of developments and to support Regional, National and local KOL activities and Jazz interests.
  • Acquires a broad understanding of local and national protocols and standards of clinical practice and trends in disease management in the US.
  • Provide clinical presentations and information in response to unsolicited questions (as appropriate) in academic, community, and healthcare provider settings in both group and one-on-one situations
  • Communicates emerging data and the clinical experience with our products through scientific exchange and peer-to-peer interactions discussing benefits and risks in an objective manner.
  • Provide scientific support for additional activities such as medical congress staffing, advisory boards, and sales training initiatives
  • Act as primary liaison to investigators interested in performing investigator-initiated trials (IIT)
  • Monitor investigator-initiated research, review study design, and oversee milestone requirements to ensure progression of investigator- or company-sponsored clinical research
  • Collaborate with medical affairs and clinical organization to support patient enrollment in our company's sponsored clinical trials with site recommendations
  • Serve (as needed) as internal scientific advisor in the evaluation of new products and technologies under consideration for portfolio enhancement/expansion
  • Contributes to the development of the US Medical Plan and provides input into local strategies and tactics.
  • Where needed, manages relevant budget to enable execution of Medical Plan tactics as part of the wider Medical Affairs team.
  • Works in a collaborative manner with cross-functional colleagues to ensure a Key Account Management approach.
  • Interacts with HCPs as a scientific resource to support activities aligned with the Medical Plan including advisory boards, speaker development and clinical trials.
  • Consistently acts to enhance Jazz Pharmaceuticals’ image as an advocate of medical advancement by using knowledge of product, disease state and pipeline products to engage healthcare providers in meaningful scientific exchange of information.
  • Document and forward reports of adverse events and product complaints according to Jazz’s policy to ensure safe and effective use of Jazz Pharmaceuticals' products.
  • Adheres to the relevant national and local Codes of Practice.
  • Behaves ethically and with integrity at all times.
  • Acts as an ambassador for Jazz Pharmaceuticals following company mission and values.
  • Keeps own written development plan and implements.
  • Prepares timely reporting according to the company needs.
Desired Qualifications
  • Knowledge of geography, healthcare environment and external experts in academia and medical community.
  • Demonstrated ability to develop trust and relationships with opinion leaders in disease states of interest.
  • Understanding of regulatory requirements for field-based personnel.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Epidiolex generated $1.1B in 2025 sales, up 9% YoY, with patents protected to late 2030s.
  • Q1 2026 revenue hit $1.1B, up 19% YoY, prompting Raymond James target raise to $239 on May 7.
  • Chimerix acquisition adds dordaviprone for H3 K27M-mutant glioma, PDUFA August 18, 2025.

What critics are saying

  • Generic competition erodes Xywav revenue as it replaces Xyrem, decelerating growth to 5.5% annually.
  • Dordaviprone fails FDA approval on August 18, 2025 PDUFA, wasting $935M Chimerix acquisition.
  • $850M exchangeable notes due 2030 dilute equity at $153.05 exchange price amid EPS decline.

What makes Jazz Pharmaceuticals unique

  • Jazz Pharmaceuticals focuses on neuroscience and oncology for rare diseases with limited treatments.
  • Xywav offers 92% less sodium than Xyrem, approved July 21, 2020, for narcolepsy in patients aged 7+.
  • Epidiolex, acquired via $7.2B GW Pharma deal in 2021, treats Lennox-Gastaut and Dravet syndromes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE